Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc bought 20,000 shares of the stock in a transaction that occurred on Thursday, April 20th. The shares were bought at an average price of $5.99 per share, for a total transaction of $119,800.00. Following the completion of the transaction, the director now directly owns […]